Internal Medicine, Hematology & Oncology · Covington, LA
NPI
1508821372
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1203 S Tyler St, Ste 100
Covington, LA, 70433
Phone (985) 892-9090
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.1M
160,805 services
Medicare patients, 2024
420
Average age 74
Drug cost, 2024
$4.5M
1,748 prescriptions
Company payments, 2025
$2,447
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James E Carinder was code J0897 (injection, denosumab, 1 mg), 8,640 times for 12 patients. In total James E Carinder billed 160,805 services in 90 codes, and Medicare paid $3.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-11-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,640 | 12 | $20.54 | $177K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 910 | 14 | $0.09 | $78.52 |
| 36415 Venipuncture Blood Collection | Office | 821 | 158 | $8.59 | $7,051 |
| 99215 Office E&M - Established | Office | 577 | 172 | $123.36 | $71K |
| 99213 Office E&M - Established | Office | 445 | 204 | $59.21 | $26K |
| J1750 Injection, iron dextran, 50 mg | Office | 286 | 18 | $13.56 | $3,878 |
| 96413 Chemotherapy Administration | Office | 276 | 25 | $86.32 | $24K |
| 96366 Intravenous Infusion, Hydration | Office | 227 | 30 | $13.78 | $3,128 |
| 96375 Injection Administration | Office | 217 | 28 | $10.38 | $2,251 |
| 96372 Injection Administration | Office | 203 | 29 | $10.02 | $2,033 |
| 96365 Intravenous Infusion, Hydration | Office | 185 | 43 | $42.67 | $7,895 |
| 96367 Intravenous Infusion, Hydration | Office | 138 | 28 | $19.23 | $2,654 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 136 | 27 | $0.63 | $85.73 |
| 96361 Intravenous Infusion, Hydration | Office | 85 | 12 | $8.77 | $745 |
| 99231 Hospital E&M - Subsequent | Facility | 58 | 19 | $37.03 | $2,148 |
By year: 2022 $3.4M for 171,691 services; 2023 $2.7M for 159,150 services; 2024 $3.1M for 160,805 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 821 | 158 | $8.59 | $7,051 |
Medicare prescription drug claims, 2024
In 2024, the drug James E Carinder prescribed most often to Medicare patients was Anastrozole, with 172 prescriptions and refills. In total James E Carinder wrote 1,748 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 172 | 484 | 51 | $3,241 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 168 | 168 | 28 | $5,023 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 97 | 97 | Under 11 | $4,120 |
| Alprazolam Generic | 89 | 95 | 16 | $403 |
| Acyclovir Generic | 73 | 105 | 11 | $713 |
| Revlimid Lenalidomide | 58 | 58 | Under 11 | $1.0M |
| Letrozole Generic | 50 | 111 | 13 | $870 |
| Zolpidem Tartrate Generic | 48 | 56 | Under 11 | $259 |
| Hydroxyurea Generic | 45 | 126 | 11 | $1,271 |
| Gabapentin Generic | 41 | 49 | Under 11 | $300 |
| Lenalidomide Generic | 40 | 40 | Under 11 | $545K |
| Ondansetron Odt Ondansetron | 36 | 43 | 16 | $621 |
| Tasigna Nilotinib Hcl | 35 | 35 | Under 11 | $689K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 30 | 30 | 12 | $458 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 29 | 64 | Under 11 | $147 |
Brand drugs: 279 claims; generic drugs: 1,469 claims; opioid claims: 319.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James E Carinder $2,447 ($2,447 in general payments such as food, travel and fees) from 40 companies. The largest payer was Novartis Pharmaceuticals Corporation with $204.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 10 | $204 |
| Pfizer Inc. PFE | 11 | $186 |
| Celgene Corporation BMY | 10 | $175 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $169 |
| Abbvie Inc. ABBV | 6 | $120 |
| Genentech USA, Inc. ROG.SW | 6 | $113 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $102 |
| Array Biopharma Inc PFE | 4 | $98.02 |
| Janssen Biotech, Inc. JNJ | 4 | $97.66 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $92.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.